Literature DB >> 12084191

Diagnostic accuracy of prostate needle biopsy.

Timothy Donahue1, Judd Moul.   

Abstract

The introduction of prostate-specific antigen screening has resulted in stage migration and an increased incidence of localized prostate cancer. In this era of increasing nonpalpable disease, it has become necessary to systematically sample the entire prostate gland. Transrectal ultrasound-guided prostate biopsy procedures have evolved greatly over the past decade from the original sextant biopsy. Technological advances, better understanding of zonal anatomy of the prostate, whole mount sectioning of radical prostatectomy specimens, and computer modeling of localized prostate cancers have all led to extended biopsy core protocols directed at the lateral zones of the gland. These have increased the diagnostic accuracy of needle biopsy and have become a standard regimen. However, it remains controversial how to proceed with repeat biopsy in the face of an initial benign diagnosis, and optimal biopsy strategy remains undefined. It is hoped that quantitative analysis of prostate biopsy histology may eventually provide some prognostic information to guide the patient and urologist in preoperative planning.

Entities:  

Mesh:

Year:  2002        PMID: 12084191     DOI: 10.1007/s11934-002-0067-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  45 in total

1.  Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer.

Authors:  J J Bauer; J Zeng; J Weir; W Zhang; I A Sesterhenn; R R Connelly; S K Mun; J W Moul
Journal:  Urology       Date:  1999-05       Impact factor: 2.649

2.  Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy.

Authors:  E A Allen; H Kahane; J I Epstein
Journal:  Urology       Date:  1998-11       Impact factor: 2.649

3.  Outcome of sextant biopsy according to gland volume.

Authors:  P I Karakiewicz; M Bazinet; A G Aprikian; C Trudel; S Aronson; M Nachabé; F Péloquint; J Dessureault; M S Goyal; L R Bégin; M M Elhilali
Journal:  Urology       Date:  1997-01       Impact factor: 2.649

Review 4.  Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy.

Authors:  P G Borboroglu; R L Sur; J L Roberts; C L Amling
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

5.  Extensive biopsy protocol improves the detection rate of prostate cancer.

Authors:  V Ravery; L Goldblatt; B Royer; E Blanc; M Toublanc; L Boccon-Gibod
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

6.  Diagnosis of prostate adenocarcinoma using transurethral resection of the prostate after multiple negative transrectal biopsies and persistently elevated prostate-specific antigen level.

Authors:  B P Vanasupa; T A Miller; B F Schwartz
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

7.  A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy.

Authors:  R J Babaian; A Toi; K Kamoi; P Troncoso; J Sweet; R Evans; D Johnston; M Chen
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

8.  Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores.

Authors:  C K Naughton; D K Ornstein; D S Smith; W J Catalona
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

9.  The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.

Authors:  T J Sebo; B J Bock; J C Cheville; C Lohse; P Wollan; H Zincke
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

10.  Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer.

Authors:  M A Levine; M Ittman; J Melamed; H Lepor
Journal:  J Urol       Date:  1998-02       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.